Published in J Extra Corpor Technol on December 01, 2007
Anti-inflammatory effect of aprotinin: a meta-analysis. J Extra Corpor Technol (2009) 1.69
Cardiopulmonary bypass during cardiac surgery modulates systemic inflammation by affecting different steps of the leukocyte recruitment cascade. PLoS One (2012) 0.91
Cardiopulmonary Bypass, Inflammation and How to Defy it: Focus on Pharmacological Interventions. Iran J Pharm Res (2012) 0.78
20 Years On: Is It Time to Redefine the Systemic Inflammatory Response to Cardiothoracic Surgery? J Extra Corpor Technol (2015) 0.77
The risk associated with aprotinin in cardiac surgery. N Engl J Med (2006) 10.98
Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA (2007) 6.04
An evidence-based review of the practice of cardiopulmonary bypass in adults: a focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg (2006) 3.09
Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest (2005) 2.75
Single crossclamp improves 6-month cognitive outcome in high-risk coronary bypass patients: the effect of reduced aortic manipulation. J Thorac Cardiovasc Surg (2005) 2.57
Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation (2007) 2.31
Risk index for perioperative renal dysfunction/failure: critical dependence on pulse pressure hypertension. Circulation (2007) 2.01
Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology (2001) 1.93
Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res (2005) 1.71
Cytokine balance and immunosuppressive changes at cardiac surgery: contrasting response between patients and isolated CPB circuits. Br J Anaesth (1995) 1.64
Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg (2005) 1.62
Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med (2005) 1.53
Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg (2004) 1.48
Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care (2003) 1.43
Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol (1997) 1.43
Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation (2000) 1.42
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev (2001) 1.37
Role of beta 2 integrins and ICAM-1 in lung injury following ischemia-reperfusion of rat hind limbs. Am J Pathol (1993) 1.24
Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J (2006) 1.24
Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med (2000) 1.23
The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg (2001) 1.11
A comparison of membrane and bubble oxygenation as used in cardiopulmonary bypass in patients. The importance of pericardial blood as a source of hemolysis. J Thorac Cardiovasc Surg (1975) 1.11
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA (2004) 1.07
Oxidative stress precedes peak systemic inflammatory response in pediatric patients undergoing cardiopulmonary bypass operation. Free Radic Biol Med (2005) 1.05
Plasma protein haptoglobin modulates renal iron loading. Am J Pathol (2005) 1.04
An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg (2000) 1.03
Administration of haptoglobin during cardiopulmonary bypass surgery. ASAIO Trans (1992) 1.03
Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg (2002) 1.02
Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg (1993) 1.01
Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg (1998) 1.01
Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am (2007) 0.99
Aprotinin improves cerebral protection: evidence from a survival porcine model. J Thorac Cardiovasc Surg (2006) 0.98
Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg (2006) 0.97
Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg (2001) 0.96
Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. J Immunol (1999) 0.96
The role of bradykinin in mediating ischemic brain edema in rats. Stroke (1993) 0.96
Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke (1991) 0.93
Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation (2005) 0.91
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg (2004) 0.88
Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion. Ann Thorac Surg (2003) 0.86
Biocompatibility in cardiopulmonary bypass. J Cardiothorac Vasc Anesth (1997) 0.83
The anticoagulant mechanism of action of heparin in contact-activated plasma: inhibition of factor X activation. Blood (1985) 0.81
Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg (1998) 0.80
Why thrombin PAR1 receptors are important to the cardiac surgical patient. J Extra Corpor Technol (2007) 0.80
Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg (1995) 0.80
Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials. Ann Thorac Surg (2004) 0.80
Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury. J Vasc Surg (2001) 0.79
A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury. Thromb Haemost (2006) 0.78
A novel device for reducing hemolysis provoked by cardiotomy suction during open heart cardiopulmonary bypass surgery: a randomized prospective study. Artif Organs (2007) 0.78
Valid comparisons of antifibrinolytic agents used in cardiac surgery. Circulation (2007) 0.77
Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. Am J Cardiol (2002) 0.77
Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation. Perfusion (2001) 0.76